{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:36:34Z","timestamp":1794998194352,"version":"4.9.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Determining whether an ipsilateral breast carcinoma recurrence is a true recurrence or a new primary remains challenging based solely on clinicopathologic features. Algorithms based on these features have estimated that up to 68% of recurrences might be new primaries. However, few studies have analyzed the clonal relationship between primary and secondary carcinomas to establish the true nature of recurrences. This study analyzed 70 breast carcinomas from 33 patients using immunohistochemistry, FISH, and massive parallel sequencing. We compared 35 primary carcinomas with the associated recurrences, identifying 24 (68.6%) as true recurrences, 7 (20%) as new primaries, and 4 (11%) as undetermined. Twenty-eight primary carcinomas were invasive carcinomas (22 of no special type, 5 invasive lobular, and 1 invasive micropapillary carcinoma), and 7 were in situ (6 ductal and 1 lobular). Time to recurrence was longer for new primaries (median 12.8\u00a0y) than for true recurrences (median 6.8\u00a0y). Among the new primary cases, 6 of 7 (85%) patients had undergone mastectomy as their initial treatment. Clinicopathologic classifications of invasive carcinomas overestimated the number of new primaries (41.6% to 68.6%), partially due to phenotype conversion in 14% of true recurrences. Although 41.7% of recurrences showed private mutations or amplifications relevant to tumor progression, such as <jats:italic toggle=\"yes\">PIK3CA, PIK3R1, MAP3K1, AKT1, GATA3, CCND1, MDM4<\/jats:italic>, or <jats:italic toggle=\"yes\">T P 5 3<\/jats:italic>; a common mutational progression pattern was not identified. Further studies, including larger series, are necessary to evaluate the prognostic significance of the molecular classification of recurrences.<\/jats:p>","DOI":"10.1097\/pas.0000000000002351","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:00:07Z","timestamp":1736402407000},"page":"294-302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Ipsilateral Breast Carcinoma Recurrence"],"prefix":"10.1097","volume":"49","author":[{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Abad","sequence":"first","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Caniego-Casas","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1986-2965","authenticated-orcid":false,"given":"Irene","family":"Carretero-Barrio","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute"},{"name":"Faculty of Medicine, Alcal\u00e1 University, Alcal\u00e1 de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Calderay-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Ram\u00f3n y Cajal University Hospital, Breast Pathology Unit, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hardisson","sequence":"additional","affiliation":[{"name":"Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute"},{"name":"Department of Pathology, Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario La Paz (IdiPAZ), La Paz University Hospital"},{"name":"Faculty of Medicine, Universidad Aut\u00f3noma de Madrid, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Palacios","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute"},{"name":"Faculty of Medicine, Alcal\u00e1 University, Alcal\u00e1 de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-5182","authenticated-orcid":false,"given":"Bel\u00e9n","family":"P\u00e9rez-Mies","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute"},{"name":"Faculty of Medicine, Alcal\u00e1 University, Alcal\u00e1 de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"R1-20250219","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/cncr.10952","article-title":"Classifying local disease recurrences after breast conservation therapy based on location and histology","volume":"95","author":"Huang","year":"2002","journal-title":"Cancer"},{"key":"R2-20250219","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2325\/jbcs.12.104","article-title":"Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors","volume":"12","author":"Komoike","year":"2005","journal-title":"Breast Cancer"},{"key":"R3-20250219","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijrobp.2010.05.063","article-title":"True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy","volume":"81","author":"Panet-Raymond","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"R4-20250219","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/SLA.0b013e318208fc2a","article-title":"Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning","volume":"253","author":"Yi","year":"2011","journal-title":"Ann Surg"},{"key":"R5-20250219","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-022-06680-7","article-title":"The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary","volume":"195","author":"Jobsen","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20250219","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.22529","article-title":"The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy","volume":"109","author":"Vicini","year":"2007","journal-title":"Cancer"},{"key":"R7-20250219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01379-3","article-title":"Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences","volume":"23","author":"Priedigkeit","year":"2021","journal-title":"Breast Cancer Res"},{"key":"R8-20250219","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2020.11.025","article-title":"A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients","volume":"156","author":"Bosma","year":"2021","journal-title":"Radiother Oncol"},{"key":"R9-20250219","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41588-022-01082-3","article-title":"Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer","volume":"54","author":"Lips","year":"2022","journal-title":"Nat Genet"},{"key":"R10-20250219","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1158\/1078-0432.CCR-22-2883","article-title":"Comparative genomic profiling of second breast cancers following first ipsilateral hormone receptor\u2013positive breast cancers","volume":"29","author":"Rassy","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R11-20250219","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R12-20250219","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/cancers11010074","article-title":"High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features","volume":"11","author":"Rosa-Rosa","year":"2019","journal-title":"Cancers"},{"key":"R13-20250219","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/PAS.0000000000001936","article-title":"The clonal relationship between the ductal and lobular components of mixed ductal-lobular carcinomas suggested a ductal origin in most tumors","volume":"46","author":"P\u00e9rez-Mies","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R14-20250219","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"R15-20250219","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"R16-20250219","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"R17-20250219","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.10.074","article-title":"Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries","volume":"79","author":"Gujral","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20250219","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12885-023-10764-y","article-title":"Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer","volume":"23","author":"Deutschmann","year":"2023","journal-title":"BMC Cancer"},{"key":"R19-20250219","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1245\/s10434-020-08516-4","article-title":"Residual glandular breast tissue after mastectomy: a systematic review","volume":"27","author":"Kaidar-Person","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R20-20250219","doi-asserted-by":"crossref","first-page":"1395970","DOI":"10.3389\/fonc.2024.1395970","article-title":"Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis","volume":"14","author":"de Baumont","year":"2024","journal-title":"Front Oncol"},{"key":"R21-20250219","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CEJ.0000000000000688","article-title":"CDH1 germline mutations in families with hereditary lobular breast cancer","volume":"31","author":"Girardi","year":"2022","journal-title":"Eur J Cancer"},{"key":"R22-20250219","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/cancers14051151","article-title":"Differences in the molecular profile between primary breast carcinomas and their cutaneous metastases","volume":"14","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2022","journal-title":"Cancers"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:00:40Z","timestamp":1739952040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002351"}},"subtitle":["True Recurrence or New Primary? A Clinicopathologic and Molecular Study"],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002351","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}